ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) today announced significant additions to its Intellectual Property (IP) portfolio, including a Canadian patent for using its proprietary porphyrin-based compound to detect cancer and trademark protection for Biomoda’s CyPath® assay kits and reagents in the European Union.
